Contract wins for life sciences business as it scales up operations

York-based life sciences firm, Aptamer Group, has hailed growing commercial momentum as it publishes its interim results for the six months ended 31 December 2022.

The York-headquartered business, which develops Optimer ® binders that can be used as synthetic alternatives to antibodies, reports revenues of £1m (H1 2022: £1.4m, FY 2022: £4m), with additional £1m worth of signed orders at 31 December 2022 and further contracts signed post-period end.

The company made a pre-tax loss of £3m (H1 2022: £1.2m loss) and an adjusted EBITDA loss of £2.5m (H1 2022: £0.6m, FY 2022: £1.7m).

Dr Arron Tolley, chief executive officer, said: “The first half of the year has seen Aptamer sign contracts across all business units, including with several top 10 pharmaceutical companies, and strong contract signing post-period.

“During the first half, we significantly scaled our operations and expanded our development capacity, underpinned by our move to custom-fitted premises.

“Looking ahead, we anticipate significantly higher revenues in the second half with a material uplift occurring in the final quarter of our financial year, as many of the current contracted development projects near completion or begin secondary phases.

“In addition, we have a strong and growing pipeline of qualified opportunities reflecting the increasing global demand for our services and recognition across the life sciences market of the technology’s capabilities and value.”

Aptamer completed a planned relocation to larger, purpose-built laboratories in November, supporting its work to scale up its operations, streamline workflows and service increased demand for Optimer binders.

Click here to sign up to receive our new South West business news...